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T
HE FUNCTIONAL AND STRUCTURAL STATUS OF THE
pulmonary vascular bed plays a pivotal role in
the presentation and outcome of the child
with congenital cardiovascular disease. However, it
is in the immediate postoperative period that the
child is most vulnerable to a sudden or sustained
increase in pulmonary vascular resistance. Following
surgery for congenital cardiac disease pulmonary
vascular reactivity is heightened and vasospastic
stimuli may result in sudden increases in pulmonary
arterial pressure and resistance resulting in acute
right heart failure, tricuspid regurgitation, systemic
hypotension, myocardial ischemia and increased
airway resistance. These episodes, called pulmonary
hypertensive crises, may be lethal events. Further-
more, mildly stimulating events precipitate similar
crises, and the crises tend to last longer and
cluster.1,2
Clearly, the pathophysiology of such events is
complex and incompletely understood by the analysis
or measurement of a single vasoactive mediator. Post-
operative pulmonary hypertension represents a com-
plex interplay between the preoperative condition of
the patient (importantly age at repair, type of lesion
and presence of a syndrome) and the inevitable dis-
ruption in the endocrine and vasoactive peptide milieu
that results from cardiac surgery. Important contribu-
tors to a milieu of enhanced vasoconstriction are
cardiopulmonary bypass, hypothermia and circulatory
arrest. Residual cardiac lesions and the sequelae of the
stress response, hypoxia, metabolic and respiratory
acidosis may all contribute additional imbalances
favoring pulmonary vasoconstriction. Postoperative
sequelae such as right and left ventricular and
atrioventricular valve dysfunction will be important
in determining how well the postoperative elevation in
pulmonary vascular resistance is tolerated. Currently,
endothelial cell dysfunction, present preoperatively
and exacerbated by perioperative influences is con-
sidered a unifying hypothesis to account for many
postoperative sequelae.3–5 However, improvements in
surgical and perioperative technique and perhaps most
importantly the trend towards performing surgical
repair early, has resulted in a marked decrease in the
incidence of symptomatic postoperative pulmonary
hypertension in countries with privileged referral
patterns. The incidence of postoperative pulmonary
hypertensive events decreased from 31% in the 1980–
84 era to 6.8% before the routine use of inhaled nitric
oxide.6 Series reflective of contemporary practice
suggest that pulmonary hypertension complicates
2.0% of patients undergoing congenital cardiac
surgery with crises occurring in 0.75%.7 However,
the mortality in those suffering a crisis remains high at
20% and pulmonary vascular disease is identified as a
major contributor to hospital length of stay and need
for prolonged mechanical ventilation.6–9
Predicting risk factors for symptomatic
postoperative pulmonary hypertension
It is difficult to predict which patients will experience
pulmonary hypertensive crises or right ventricular
failure with low cardiac output postoperatively.
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Patients who experience crises usually have reactive
pulmonary vascular beds. Patients dying from pul-
monary arterial hypertensive crises have increased
muscularization of the small pulmonary arterioles
without changes of irreversible pulmonary vascular
disease.1 Patients who undergo surgical repair with
fixed elevations of pulmonary vascular resistance
may not experience crises but are at risk of right
ventricular failure especially if there is postoperative
deterioration of atrioventricular valvar regurgita-
tion and right ventricular function. Most patients
with high flow, high-pressure and low pulmonary
vascular resistance lesions will not require therapy
for pulmonary arterial hypertension postopera-
tively.7 There is, therefore, considerable value in
attempting to select high-risk patients for special
monitoring or even prophylactic therapy. Risk
stratification is mainly clinical because lung biopsy
and cardiac catheterization are not performed
routinely prior to cardiac surgery. Patients with
clinical or echocardiographic signs of an elevated
pulmonary vascular resistance may benefit from
preoperative cardiac catheterization to assess risk
and operability. Preoperative lung biopsy alone has a
limited capacity to define operability compared with
hemodynamic assessments. Patients with extracardiac
syndromes (especially Down’s syndrome) seem to be
at increased risk of pulmonary hypertensive events.7
Patients with pulmonary venous or left atrial hyper-
tension whether following pulmonary vein surgery
or from left heart abnormalities (hypoplasia, mitral
regurgitation or stenosis) have extremely reactive
pulmonary vasculature. In general, for all lesions,
early repair appears to confer benefit on postoperative
pulmonary vascular complications and this applies
to truncus arteriosus, atrioventricular septal defect,
ventricular septal defect and transposition of the great
arteries with ventricular septal defect.7,10,11 Patients
with aortic origin of a pulmonary artery, truncus
arteriosus and single ventricle lesions with unrest-
rictive pulmonary blood flow have markedly reactive
pulmonary vascular beds in the postoperative period
especially if intervention is delayed beyond the age
of 2 months.10,12 All patients with problematic
postoperative pulmonary hypertension should under-
go investigation to exclude residual or overlooked
left-to-right intracardiac shunts. In general, there is
consensus that early repair of uncomplicated left to
right shunt lesions in the first 6 months of life
reduces the risk of postoperative pulmonary hyper-
tension in patients with high-risk diagnoses. Thus a
profile of a high-risk patient might be a 14-month-
old child with Down’s syndrome, an unbalanced
atrioventricular canal defect but not sufficiently
to preclude a biventricular repair. At preoperative
cardiac catheterization the pulmonary vascular
resistance index is calculated at 6.0 Wood units m2.
The patient is reactive to inhaled nitric oxide and
hyperoxia. The lowest pulmonary vascular resistance
index is 1.5 Wood units m2, with a shunt of more
than 5:1 from left to right. The child undergoes
repair, and postoperatively there is mitral insuffi-
ciency and stenosis, and tricuspid valvar regurgita-
tion.
The use of pulmonary arterial catheters
If it is difficult to predict who will develop symp-
tomatic postoperative pulmonary hypertension the
question may be asked whether all patients should
have a pulmonary arterial catheter to monitor
pulmonary arterial pressure. The use of pulmonary
arterial lines is associated with low morbidity
particularly when used in an institution experienced
with pulmonary arterial line management. The
adverse event associated with a short-term pulmon-
ary arterial line is the risk of bleeding after removal
especially in the presence of elevated pulmonary
arterial and right ventricular pressures.13 The risk
may be mitigated by placing the pulmonary arterial
line through the right atrium or muscular right
ventricular infundibulum. However, the incidence
of symptomatic pulmonary arterial hypertension
is now so low that it may no longer be justified to
place a line in all patients undergoing repair of high
pressure or high flow lesions or both. Pulmonary
arterial lines focus the attention of caregivers on
the pulmonary arterial pressure and this may parad-
oxically delay progress through the cardiac intensive
care unit, as there is a tendency to react to each
fluctuation in pulmonary arterial pressure. However,
for the evaluation of new postoperative therapies
whether specific for the pulmonary vasculature or
otherwise, pulmonary arterial lines are essential to
provide data on cardiac output as well calculate
pulmonary vascular resistance. Often the decision to
place a pulmonary arterial line is made by necessity in
the operating room if elevated pulmonary arterial
pressures (mean pulmonary arterial pressure greater
than 25mmHg or more than 50–60% of systemic
pressure) are encountered or if there is the need for
specific pulmonary vasodilator therapy to separate
from cardiopulmonary bypass. Echocardiography
Patients most at risk of pulmonary hypertensive crises who require
special monitoring are older at repair, with a high degree of
reactivity, with an extra cardiac syndrome, and an elevated
pulmonary venous or left atrial pressure. In addition, patients with
decreased right ventricular function or tricuspid valve regurgitation
maybe intolerant of even mild increases in pulmonary vascular
resistance and benefit from pulmonary vasodilator therapy.
Class: I. Level of evidence: B.
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accurately predicts right ventricular and pulmonary
arterial pressure through interrogation of tricuspid
regurgitation and pulmonary insufficiency veloci-
ties. Imaging of the right ventricle and evaluation of
potential residual lesions is also useful. However,
echocardiographic assessment in the sick unstable post-
operative patient with limited windows is operator-
dependant, and while echocardiographic assessment
is extremely valuable it may not be feasible in off-
hours or during a crisis. After the crisis has resolved
pulmonary arterial pressures may be misleadingly
normal. Right ventricular pressure may not predict
pulmonary arterial pressure if there is obstruction
of the right ventricular outflow tract or branch
pulmonary artery. Nevertheless, echocardiography
together with mixed venous saturation and central
venous pressure monitoring are powerful tools in
the assessment of pulmonary hypertensive patients.
The use of small implantable devices that mon-
itor pulmonary arterial pressure have not been used
extensively in this population. If the patient is
at risk for sustained pulmonary hypertension and
prolonged postoperative therapy is likely, these
devices may have a place in monitoring.
The management of postoperative pulmonary
hypertension
There are no clear pulmonary arterial pressure or
pulmonary vascular resistance measurements that
indicate a need for postoperative therapy. However,
consensus would indicate that patients with post-
operative pulmonary hypertension (mean pulmonary
arterial pressure greater than 25mmHg or more than
50–60% of systemic pressure) associated with signs of
low cardiac output or its surrogates are concerning
and indicative of the need to consider specific therapy.
Prevention of pulmonary hypertensive crises is a
worthy goal of treatment but elusive because of the
difficulty in predicting who will suffer a crisis and the
rarity of crises in contemporary practice.
Management of symptomatic pulmonary hyperten-
sion involves avoiding or mitigating vasoconstrictive
triggers and the use of pulmonary vascular specific
therapies. It has been observed that pulmonary hyper-
tensive crises may be triggered by stressful stimuli
including tracheal suctioning, pain and anxiety. The
use of high dose fentanyl to suppress the stress
response in neonates undergoing surgery has been
established in randomized controlled studies.14,15 It
has become common practice to use continuous
fentanyl infusions with muscle relaxation through
the first postoperative night. Supplemental fentanyl
prior to endotracheal suctioning will suppress the
pulmonary vasoconstrictor response providing suction
is performed without causing hypoxia or hypercarbia.
Hypoxia is a potent pulmonary vasoconstrictor and
should be avoided in high-risk patients. However,
there is less evidence to suggest that hyperoxia is as
potent a vasodilator as in the preoperative patient.
Mechanical ventilation with high concentrations of
oxygen for prolonged periods should be avoided.
Avoiding hypoxia is extremely important and ventila-
tion with supplemental oxygen is used often to
prevent triggering pulmonary vasoconstriction. Acido-
sis, whether respiratory or metabolic, is a powerful
vasoconstrictor and alkalosis is as effective a pulmon-
ary vasodilator as inhaled nitric oxide.16,17 Hyperven-
tilation or the infusion of sodium bicarbonate are
extremely useful strategies in the immediate manage-
ment of pulmonary hypertensive crises while more
specific strategies are put in place. However, there are
drawbacks to prolonged induction of therapeutic
alkalosis. The disadvantages of prolonged high
mechanical ventilator settings include pulmonary
barotrauma and reduction of cardiac output espe-
cially in the face of poor right ventricular function.
Infusions of sodium bicarbonate decrease cardiac
output and cerebral blood flow and increase central
venous pressure and systemic vascular resistance.
Nevertheless, avoiding acidosis is as important as
avoiding hypoxia to prevent pulmonary vasoconstric-
tion, and most would advocate a pH>7.4 in patients
at risk or 7.5 in refractory pulmonary arterial hyper-
tension. In patients with a surgically created right-
to-left ‘‘pop off’’ and hypoxemia, some would advocate
adjusting the hemoglobin to a level commensurate
with systemic arterial oxygen saturations.
Inhaled nitric oxide has become the accepted therapy
for postoperative pulmonary arterial hypertension.
Advantages of inhaled nitric oxide include the ease of
delivery, minimal side effect profile and specificity for
the pulmonary vascular bed. Nitric oxide is endothe-
lial cell derived and activates guanylate cyclase to
cause vascular vasodilation through a cyclic guanosine
monophosphate dependant mechanism. Nitric oxide
is inactivated rapidly by hemoglobin. If inhaled,
nitric oxide causes selective pulmonary vasodilation
because of rapid inactivation by hemoglobin before
transit through the pulmonary vascular bed. Thus
unlike non-specific pulmonary vasodilators, nitric
oxide decreases intrapulmonary shunt fraction and
will often improve systemic arterial oxygenation.
Direct measurement of pulmonary artery pressure is recommended if
mean pulmonary artery pressure is .25mmHg (or 50–60% of
systemic pressure) or specific pulmonary vasodilator therapy is used in
the operating room. However, there is no evidence to suggest that direct
pulmonary artery pressure measurements improve outcome.
Echocardiography together with mixed venous saturation and central
venous pressure monitoring may provide adequate information for
patient treatment if direct measurements are unavailable.
Class: I. Level of evidence: C.
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Inhaled nitric oxide has been shown in many
studies to be an effective pulmonary vasodilator in
postoperative patients with congenital cardiac dis-
ease.3,16,18–22 The doses of nitric oxide have ranged
from 2–80ppm.19 There does not appear to be any
clear benefit from doses in excess of 10–20ppm for
routine use. It is often forgotten that the measured
nitric oxide is a concentration at the proximal endo-
tracheal tube and may not reflect the dose delivered to
the alveolus. However, side effects such as methemo-
globinemia are rare with doses less than 80 ppm even
for prolonged periods. Nevertheless it is prudent to
measure levels of methemoglobin daily while nitric
oxide is administered. Commercially available delivery
devices and ventilators without mechanical bellows
have reduced concerns with nitric dioxide and issues
surrounding gas scavenging.23,24 Thus, inhaled nitric
oxide may reduce mortality after repair of atrioven-
tricular canal defects.22 In a randomised double
blind controlled trial, treatment with nitric oxide
reduced pulmonary arterial hypertensive crises and
shortened time to reach criteria for extubation.
However, ventilator days were not significantly
different, perhaps in view of the prolonged nitric
oxide weaning protocol used to avoid rebound
pulmonary hypertension.25 One randomized and
controlled study failed to show an advantage to
inhaled nitric oxide when used against a back-
ground of presumably hyperoxic alkalosis.26
Rebound pulmonary hypertension has been des-
cribed upon rapid withdrawal of nitric oxide or
withdrawal prior to resolution of pulmonary
vascular constriction.27,28 Rebound may result in
considerable hemodynamic instability, ventilation
difficulty, and hypoxia and require reinstitution of
inhaled nitric oxide, or adjunctive therapies such as
ventilation, and hyperoxic alkalosis. The effects can
be minimized by slow weaning, in particular the
last 5 ppm. The need, however, for prolonged
inhaled nitric oxide therapy may delay tracheal
extubation, and transition to oral or intermittently
inhaled pulmonary vasodilators may be considered
at this point in therapy. A randomized controlled
blinded study has demonstrated that oral sildenafil
(a type 5 phosphodiesterase inhibitor) at 0.3–
0.5mg/kg results in abolition of rebound and
facilitates shorter times to extubation and intensive
care stay.29 This strategy also may be useful in
transitioning patients to chronic therapy.30 Despite
attention to adjunctive measures and the use of
inhaled nitric oxide, there are patients whose pul-
monary arterial hypertension is refractory to therapy.
Sildenafil intravenously or orally and inhaled Iloprost
and intravenous prostacyclin may be used to augment
a pulmonary vasodilator response to inhaled nitric
oxide.
Drugs, which augment cardiac output as well as
dilate the pulmonary vascular bed, such as milrinone,
levosimendan, and nesiritide may be useful adjuncts
providing the patient is tolerant of systemic vasodila-
tion. Vasopressin is a pulmonary vasodilator and
systemic vasoconstrictor, and may be useful in the
management of systemic hypotension associated with
pulmonary hypertension. Strategies to prevent pul-
monary hypertension postoperatively by initiating
therapies prior to or during cardiopulmonary bypass
such as citrulline to augment nitric oxide production,
sildenafil to increase cyclic guanosine monophosphate
levels or endothelin receptor antagonists to diminish
the effects of elevated endothelin 1 levels are promis-
ing ideas and potentially fruitful areas of research.31,32
References
1. Hopkins RA, Bull C, Haworth SG, de Leval MR, Stark J.
Pulmonary hypertensive crises following surgery for congenital
heart defects in young children. Eur J Cardiothorac Surg 1991; 5:
628–634.
2. Wheller J, George BL, Mulder DG, Jamarkani JM. Diagnosis and
management of postoperative pulmonary hypertensive crisis.
Circulation 1979; 60: 1640–1644.
3. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of
inhaled nitric oxide and acetylcholine in the evaluation of
pulmonary hypertension and endothelial function after cardio-
pulmonary bypass. Circulation 1993; 88[part 1]: 2128–2138.
4. Komai H, Adatia I, Elliott MJ, de Leval MR, Haworth SG.
Increased plasma levels of endothelin-1 after cardiopulmonary
bypass in patients with pulmonary hypertension and congenital
heart disease. J Thorac Cardiovasc Surg 1993; 106: 473–478.
5. Adatia I, Barrow S, Stratton P, Ritter J, Haworth S. Effect of intra-
cardiac repair on biosynthesis of thromboxane A2 and prostacyclin in
children with a left to right shunt. Br Heart J 1994; 72: 452–456.
6. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary
hypertension after operations for congenital heart disease: analysis
of risk factors and management. J Thorac Cardiovasc Surg 1996;
112: 1600–1607; discussion 1607-1609.
7. Lindberg L, Olsson AK, Jogi P, Jonmarker C. How common is
severe pulmonary hypertension after pediatric cardiac surgery?
J Thorac Cardiovasc Surg 2002; 123: 1155–1163.
8. Brown KL, Ridout DA, Goldman AP, Hoskote A, Penny DJ.
Risk factors for long intensive care unit stay after cardiopulmon-
ary bypass in children. Crit Care Med 2003; 31: 28–33.
1. Blunting the stress response with narcotics and muscle relaxation,
avoiding hypoxia and acidosis and augmenting cardiac output
are important adjunctive treatments for patients at risk of
pulmonary hypertensive crises.
Class: I. Level of evidence: B.
2. Inhaled nitric oxide decreases pulmonary artery pressure and
vascular resistance, and may prevent pulmonary hypertensive
crises and shorten time to reach extubation criteria in patients
with postoperative pulmonary artery hypertension. Sildenafil
effectively prevents rebound pulmonary hypertension associated
with withdrawal of inhaled nitric oxide therapy, and reduces
mechanical ventilation and intensive care unit stay.
Class: I. Level of evidence: B.
26 Cardiology in the Young: Volume 19 E-Supplement 1 May 2009
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1047951109003916
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 19:48:42, subject to the Cambridge Core terms of use, available at
9. Schulze-Neick I, Li J, Penny DJ, Redington AN. Pulmonary
vascular resistance after cardiopulmonary bypass in infants: effect
on postoperative recovery. J Thorac Cardiovasc Surg 2001; 121:
1033–1039.
10. Hanley F, Heinemann M, Jonas R, et al. Repair of truncus
arteriosus in the neonate. J Thorac Cardiovasc Surg 1993; 105:
1047–1056.
11. Haworth SG. Pulmonary vascular disease in different types of
congenital heart disease. Br Heart J 1984; 52: 557–571.
12. Brizard CP, Cochrane A, Austin C, Nomura F, Karl TR.
Management strategy and long-term outcome for truncus
arteriosus. Eur J Cardiothorac Surg 1997; 11: 687–695;
discussion 695-686.
13. Flori HR, Johnson LD, Hanley FL, Fineman JR. Transthoracic
intracardiac catheters in pediatric patients recovering from con-
genital heart defect surgery: associated complications and
outcomes. Crit Care Med 2000; 28: 2997–3001.
14. Anand KJ, Hansen DD, Hickey PR. Hormonal-metabolic stress
responses in neonates undergoing cardiac surgery. Anesthesiology
1990; 73: 661–670.
15. Anand KJ, Sippell WG, Aynsley-Green A. Randomised trial of
fentanyl anaesthesia in preterm babies undergoing surgery: effects
on the stress response. Lancet 1987; 1 (8524): 62–66.
16. Morris K, Beghetti M, Petros A, Adatia I, Bohn D. Comparison
of hyperventilation and inhaled nitric oxide for pulmonary
hypertension after repair of congenital heart disease. Crit Care
Med 2000; 28: 2974–2978.
17. Chang AC, Zucker HA, Hickey PR, Wessel DL. Pulmonary
vascular resistance in infants after cardiac surgery: role of carbon
dioxide and hydrogen ion. Crit Care Med 1995; 23: 568–574.
18. Beghetti M, Habre W, Berner M. Continuous low dose inhaled
nitric oxide for treatment of severe pulmonary hypertension after
cardiac surgery in paediatric patients. Br Heart J 1995; 73: 65–68.
19. Miller OI, Celermeyer DS, Deanfield JE, Macrae DJ. Very low
dose inhaled nitric oxide: a selective pulmonary vasodilator after
operations for congenital heart disease. J Thorac Cardiovasc Surg
1994; 108: 487–494.
20. Journois D, Pouard P, Mauriat P, Malhe`re T, Vouhe´ P, Safran D.
Inhaled nitric oxide as a therapy for pulmonary hypertension after
operations for congenital heart defects. J Thorac Cardiovasc Surg
1994; 107: 1129–1135.
21. Russell IA, Zwass MS, Fineman JR, et al. The effects of inhaled
nitric oxide on postoperative pulmonary hypertension in infants
and children undergoing surgical repair of congenital heart
disease. Anesth Analg 1998; 87: 46–51.
22. Journois D, Baufreton C, Mauriat P, Pouard P, Vouhe P, Safran D.
Effects of inhaled nitric oxide administration on early post-
operative mortality in patients operated for correction of atrio-
ventricular canal defects. Chest 2005; 128: 3537–3544.
23. Wessel DL, Adatia I, Thompson JE, Hickey PR. Delivery and
monitoring of inhaled nitric oxide in patients with pulmonary
hypertension. Crit Care Med 1994; 22: 930–938.
24. Miller OI, Celermajer DS, Deanfield JE, Macrae DJ. Guidelines
for the safe administration of inhaled nitric oxide. Arch Dis Child
1994; 70: F47–F49.
25. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer
DS. Inhaled nitric oxide and prevention of pulmonary hyperten-
sion after congenital heart surgery: a randomised double-blind
study. Lancet 2000; 356: 1464–1469.
26. Day RW, Hawkins JA, McGough EC, Crezee KL, Orsmond GS.
Randomized controlled study of inhaled nitric oxide after
operation for congenital heart disease. Ann Thorac Surg 2000;
69: 1907–1912; discussion 1913.
27. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension
after inhalation of nitric oxide. Ann Thorac Surg 1996; 62:
1759–1764.
28. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound
pulmonary hypertension on withdrawal from inhaled nitric
oxide. Lancet 1995; 346 (8966): 51–52.
29. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ,
Shekerdemian LS. Sildenafil prevents rebound pulmonary hyper-
tension after withdrawal of nitric oxide in children. Am J Respir
Crit Care Med 2006; 174: 1042–1047.
30. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial
effect of oral sildenafil therapy on childhood pulmonary arterial
hypertension: twelve-month clinical trial of a single-drug, open-
label, pilot study. Circulation 2005; 111: 3274–3280.
31. Ikonomidis JS, Hilton EJ, Payne K, et al. Selective endothelin-A
receptor inhibition after cardiac surgery: a safety and feasi-
bility study. Ann Thorac Surg 2007; 83: 2153–2160; discussion
2161.
32. Barr FE, Tirona RG, Taylor MB, et al. Pharmacokinetics and
safety of intravenously administered citrulline in children
undergoing congenital heart surgery: potential therapy for post-
operative pulmonary hypertension. J Thorac Cardiovasc Surg
2007; 134: 319–326.
Adatia and Beghetti: Postoperative pulmonary hypertension 27
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1047951109003916
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 19:48:42, subject to the Cambridge Core terms of use, available at
